Contamination Control & Annex 1

Lessons From Major Contamination Events in Sterile Manufacturing Critical Lessons From Contamination Events in Aseptic Manufacturing and Annex 1 Compliance Ensuring sterility assurance during aseptic manufacturing remains a primary focus for pharmaceutical manufacturers globally. Over the past decades, multiple major contamination events have exposed vulnerabilities in contamination control systems, especially within Grade A and B…

Read More “Lessons From Major Contamination Events in Sterile Manufacturing” »

Aligning Contamination Control Strategy With Corporate Sterility Assurance Policies Step-by-Step Guide to Aligning Contamination Control Strategy With Corporate Sterility Assurance Policies The pharmaceutical industry’s sterile manufacturing sectors face increasingly stringent requirements to ensure product sterility and patient safety. A robust contamination control strategy (CCS) aligned with corporate sterility assurance policies is critical for compliance with…

Read More “Aligning Contamination Control Strategy With Corporate Sterility Assurance Policies” »

How Annex 1 Has Changed the Role of Microbiology in GMP Sites How Annex 1 Has Changed the Role of Microbiology in GMP Sites: A Step-by-Step Guide For pharmaceutical manufacturing sites engaged in aseptic manufacturing, understanding and complying with Annex 1 of the EU GMP guidelines has become paramount. The recent revision of Annex 1…

Read More “How Annex 1 Has Changed the Role of Microbiology in GMP Sites” »

Periodic Review of CCS: Triggers, Scope and Outputs | Pharma GMP Guide Conducting a Periodic Review of Contamination Control Strategy (CCS): Step-by-Step Guide for Aseptic Manufacturing Ensuring the robustness and compliance of contamination control strategies (CCS) within aseptic manufacturing environments is critical for sterility assurance and patient safety. Regulatory authorities in the US, UK, and…

Read More “Periodic Review of CCS: Triggers, Scope and Outputs” »